SURMOUNT-1: Tirzepatide vs Placebo for Obesity Over 72 Weeks

What was the SURMOUNT-1 trial?

SURMOUNT-1 was the first large phase 3 trial to test tirzepatide specifically for weight loss in people without diabetes, and it produced the numbers most often quoted when the drug comes up.

It was a randomized, double-blind, placebo-controlled trial sponsored by Eli Lilly and published in the New England Journal of Medicine in 2022 (PMID 35658024). Tirzepatide is a single molecule that activates two gut-hormone receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — which is why it is described as a dual agonist rather than a plain GLP-1 drug. The trial is registered on ClinicalTrials.gov as NCT04184622. Its job was narrow and specific: measure how much weight adults with obesity lost on tirzepatide compared with placebo, over 72 weeks, with both groups receiving the same lifestyle support.

Because it was double-blind and placebo-controlled, neither participants nor investigators knew who was receiving the drug, which is the design that lets a trial separate a real drug effect from expectation and from the diet-and-activity programme everyone followed. For the wider evidence picture across this drug class, see our pillar guide to peptides for weight loss.

Who was in it?

SURMOUNT-1 randomized 2,539 adults. To be eligible, participants had to have a body-mass index of 30 or more (the clinical threshold for obesity), or a BMI of 27 or more together with at least one weight-related complication such as hypertension or dyslipidemia. Crucially, people with type 2 diabetes were excluded — that population was studied separately in SURMOUNT-2. The mean baseline body weight was 104.8 kg, so this was a group with substantial excess weight rather than mild overweight.

That enrolment matters when reading the results. The figures below describe adults with obesity and no diabetes who were also following a reduced-calorie diet and increased physical activity, which is the setting the trial was built to test. They do not automatically transfer to people outside those criteria.

What did participants receive?

Participants were assigned to once-weekly subcutaneous tirzepatide at a maintenance dose of 5 mg, 10 mg or 15 mg, or to a matching placebo injection. The maintenance doses were reached through gradual escalation from a low starting dose, a standard approach in this class intended to reduce gastrointestinal side effects while the body adjusts. Every group, including placebo, also received lifestyle counselling on diet and activity for the full 72 weeks.

The description above is a report of what the trial administered. It is not a protocol to follow, a dosing schedule, or a suggestion that any reader should take tirzepatide — those are matters for a prescriber. The same active molecule is marketed as Mounjaro for type 2 diabetes and as Zepbound for weight management; our tirzepatide research summary covers the drug across its indications.

Primary results

The headline finding was a clear, dose-related separation from placebo. At 72 weeks, mean percentage change in body weight was:

• −15.0% on tirzepatide 5 mg (95% CI, −15.9 to −14.2)
• −19.5% on tirzepatide 10 mg (95% CI, −20.4 to −18.5)
• −20.9% on tirzepatide 15 mg (95% CI, −21.8 to −19.9)
• −3.1% on placebo (95% CI, −4.3 to −1.9)

Even the lowest tirzepatide dose produced roughly five times the mean weight loss seen with lifestyle support alone, and the effect grew with dose. These are averages from the trial's primary analysis; individual results in any trial vary widely around the mean, and the placebo arm shows what the diet-and-activity programme achieved on its own.

Secondary results

Beyond the average, SURMOUNT-1 reported how many participants crossed specific weight-loss thresholds — a way of showing that the effect was widespread rather than driven by a handful of large responders. The table shows the verified responder figures from the trial.

The great majority of participants on tirzepatide reached at least 5% loss — the threshold generally regarded as clinically meaningful — versus about a third on placebo. And 57% of those on the 15 mg dose reached at least 20% loss, a magnitude rarely seen with drug therapy before this class, against 3% on placebo. (A dash means the trial's abstract did not report that specific figure for that dose, so it is left out rather than estimated.)

Safety and side effects reported

The most common adverse events with tirzepatide were gastrointestinal — chiefly nausea, diarrhea and constipation. In line with the rest of this drug class, these were generally mild to moderate and clustered during the dose-escalation period, easing as the dose stabilized.

Adverse events led to treatment discontinuation in 4.3%, 7.1% and 6.2% of participants on the 5, 10 and 15 mg doses respectively, compared with 2.6% on placebo. In other words, most participants tolerated the drug well enough to stay on it for the full 72 weeks, though a modest and dose-influenced minority stopped because of side effects. As with any medicine, the safety profile is a matter for a clinician to weigh against an individual's history; this is a summary of what the trial reported, not a safety assessment for any reader.

Limitations and what it does not prove

A large, clean efficacy result still has boundaries. SURMOUNT-1 ran for 72 weeks, so it does not, by itself, establish what happens over many years or after treatment stops — durability and maintenance are separate questions this trial was not designed to answer. It also enrolled adults with obesity and without diabetes, so its numbers should not be read as applying to people with type 2 diabetes, to adolescents, or to those outside the entry criteria.

Being a weight-and-safety trial, it measured how much weight participants lost and how well they tolerated the drug; it was not powered as a cardiovascular-outcomes trial, so it does not on its own demonstrate reductions in heart attacks, strokes or mortality. Finally, mean figures describe the average participant, not a guaranteed personal result, and the whole trial was conducted alongside a structured diet-and-activity programme rather than in place of one. None of this diminishes the finding — it just marks where the evidence ends.

Why the SURMOUNT-1 trial matters

SURMOUNT-1 mattered because it showed, in a rigorous phase 3 design, that a dual GIP/GLP-1 agonist could push mean weight loss toward 20% — a level that had previously been associated more with bariatric surgery than with a once-weekly injection. It was a pivotal trial behind tirzepatide's approval for chronic weight management (marketed as Zepbound), and it reset expectations for what pharmacological obesity treatment could achieve.

It also set a benchmark that later trials were measured against, including the head-to-head comparison with semaglutide in SURMOUNT-5. If you are weighing how tirzepatide and semaglutide stack up, our tirzepatide vs semaglutide comparison lays out the trial-by-trial picture. For the broader landscape of which weight-loss compounds actually have human data, start with the peptides for weight loss guide, or browse the full research hub.

Frequently asked questions

Sources

This summary traces to the peer-reviewed publication and the trial registration:

1. Tirzepatide Once Weekly for the Treatment of Obesity — New England Journal of Medicine, 2022; PubMed 35658024.
2. SURMOUNT-1 (tirzepatide) — ClinicalTrials.gov NCT04184622.
3. Drug reference record: tirzepatide.

Related research